Evidence map›Paper›PMID 35155636›Full record

ArticleFrontiers in cardiovascular medicine2022

Cardio-Oncology in the COVID Era (Co & Co): The Never Ending Story.

Irma Bisceglia, Maria Laura Canale, Giuseppina Gallucci, Fabio Maria Turazza, Chiara Lestuzzi, Iris Parrini, Giulia Russo, Nicola Maurea, Vincenzo Quagliariello, Stefano Oliva and 10 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 16 institutions in 1 country.

Irma BiscegliaIntegrated Cardiology Services, Cardio-Thoracic-Vascular Department, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.
Maria Laura CanaleCardiology Department, Nuovo Ospedale Versilia Lido di Camaiore Lucca, Camaiore, Italy.
Giuseppina GallucciCardio-Oncology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Referral Cancer Center of Basilicata, Rionero in Vulture, Italy.
Fabio Maria TurazzaCardiology Department, National Cancer Institute Foundation, Milan, Italy.
Chiara LestuzziAzienda Sanitaria Friuli Occidentale (ASFO) Cardiac and Cardio-Oncologic Rehabilitation Service at Centro di Riferimento Oncologico (CRO), National Cancer Institute, Aviano, Italy.
Iris ParriniCardiology Department, Ospedale Mauriziano Umberto I, Turin, Italy.
Giulia RussoCardiovascular and Sports Medicine Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI) Trieste, Trieste, Italy.
Nicola MaureaCardiology Department, G. Pascale National Cancer Institute Foundation (IRCCS), Naples, Italy.
Vincenzo QuagliarielloCardiology Department, G. Pascale National Cancer Institute Foundation (IRCCS), Naples, Italy.
Stefano OlivaCardio-Oncology Department, Istituto Tumori Giovanni Paolo II, Bari, Italy.
Stefania Angela Di FuscoClinical and Rehabilitation Cardiology Department, Ospedale San Filippo Neri, Rome, Italy.
Fabiana LucàCardiology Department, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy.
Luigi TarantiniCardiology Department, Santa Maria Nuova Hospital, Reggio Emilia, Italy.
Paolo TrambaioloDivisione di Cardiologia, Arcispedale S. Maria Nuova, Azienda Unità Sanitaria Locale-IRCCS di Reggio-Emilia, Reggio Emilia, Italy.
Antonella MoreoA. De Gasperis Cardio Center, Aziende Socio Sanitarie Territoriali (ASST) Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Giovanna GeraciCardiology Unit, Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy.
Domenico GabrielliCardio-Thoracic-Vascular Department, San Camillo-Forlanini Hospital, Rome, Italy.
Michele Massimo GuliziaCardiology Department, Garibaldi Hospital, Catania, Italy.
Fabrizio OlivaDipartimento Cardiotoracovascolare, Cardiology 1-Cath Lab, Coronary Care Unit (CCU), ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Furio ColivicchiClinical and Rehabilitation Cardiology Department, Ospedale San Filippo Neri, Rome, Italy.
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITOspedale San Filippo Neri · ITAzienda ospedaliera "Bianchi-Melacrino-Morelli" · ITAzienda Ospedaliera San Camillo-Forlanini · ITAzienda Sanitaria Unità Locale di Reggio Emilia · ITAzienda Sanitaria Universitaria Integrata di Trieste · ITAzienda Socio Sanitaria Territoriale Lariana · ITCarlo Forlanini Hospital · ITCentro di Riferimento Oncologico · ITCentro di Riferimento Oncologico della Basilicata · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITIstituto Tumori Bari · ITOspedale Garibaldi · ITOspedale Versilia · ITOspedale Vincenzo Cervello · ITOspedali Riuniti Umberto I · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The pathophysiology of some non-communicable diseases (NCDs) such as hypertension, cardiovascular disease (CVD), diabetes, and cancer includes an alteration of the endothelial function. COVID-19 is a pulmonary and vascular disease with a negative impact on patients whose damaged endothelium is particularly vulnerable. The peculiar SARS-CoV-2-induced "endothelitis" triggers an intriguing immune-thrombosis that affects both the venous and arterial vascular beds. An increased liability for infection and an increased likelihood of a worse outcome have been observed during the pandemic in patients with active cancer and in cancer survivors. "Overlapping commonalities" between COVID-19 and Cardio-Oncology have been described that include shared phenotypes of cardiovascular toxicities such as left ventricular dysfunction, ischemic syndromes, conduction disturbances, myocarditis, pericarditis and right ventricular failure; shared pathophysiologic mechanisms such as inflammation, release of cytokines, the renin-angiotensin-aldosterone-pathway, coagulation abnormalities, microthrombosis and endothelial dysfunction. For these features and for the catalyst role of NCDs (mainly CVD and cancer), we should refer to COVID-19 as a "syndemic." Another challenging issue is the persistence of the symptoms, the so-called "long COVID" whose pathogenesis is still uncertain: it may be due to persistent multi-organ viral attacks or to an abnormal immune response. An intensive vaccination campaign is the most successful pharmacological weapon against SARS-CoV-2, but the increasing number of variants has reduced the efficacy of the vaccines in controlling SARS-CoV-2 infections. After a year of vaccinations we have also learned more about efficacy and side-effects of COVID-19 vaccines. An important byproduct of the COVID-19 pandemic has been the rapid expansion of telemedicine platforms across different care settings; this new modality of monitoring cancer patients may be useful even in a post pandemic era. In this paper we analyze the problems that the cardio-oncologists are facing in a pandemic scenario modified by the extensive vaccination campaign and add actionable recommendations derived from the ongoing studies and from the syndemic nature of the infection.

Indexed as

cancercardiotoxicitycardiovascular diseaseCOVID-19SARS-CoV-2syndemictelehealth

Identifiers

PMID35155636
PMCPMC8831543
OpenAlexW4210799697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.